share_log

Press Release: Sanofi Initiates Phase 3 Program for PCV21 and Expands Collaboration With SK Bioscience for Next-generation Pneumococcal Conjugate Vaccines

Press Release: Sanofi Initiates Phase 3 Program for PCV21 and Expands Collaboration With SK Bioscience for Next-generation Pneumococcal Conjugate Vaccines

新闻稿:赛诺菲安万特启动PCV21的第三阶段计划,并扩大与SK生物的合作,开发下一代肺炎球菌结合疫苗。
GlobeNewswire ·  12/23 14:00

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

赛诺菲安万特启动PCV21的三期计划,并与SK生物科学扩大合作,开发下一代肺炎球菌结合疫苗

  • Pneumococcal disease remains a major global health challenge despite the availability of current vaccines
  • This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers
  • 尽管目前疫苗可用,肺炎球菌疾病仍然是一个重大的全球健康挑战
  • 这款21价肺炎球菌结合疫苗(PCV21)是第一个在婴幼儿中进入三期试验的超过20种血清型的肺炎球菌结合疫苗候选药物

Paris, December 23, 2024. Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both pediatric and adult populations, reaffirming their commitment to fighting pneumococcal disease.

巴黎,2024年12月23日。赛诺菲安万特与SK生物科学在肺炎球菌疫苗合作的新篇章中达成了一项扩大协议,开发、许可和商业化下一代肺炎球菌疫苗,面向儿童和成人人群,重申了他们对抗击肺炎球菌疾病的承诺。

Despite decades of public health vaccination programs, invasive pneumococcal disease (IPD) continues to inflict a substantial burden of disease, primarily due to Streptococcus pneumoniae serotypes that are not included in currently available conjugate vaccines. Next-generation PCVs have the potential to extend vaccine coverage of disease-causing serotypes.

尽管进行了数十年的公共卫生疫苗接种计划,侵袭性肺炎球菌疾病(IPD)继续造成相当大的疾病负担,这主要是由于目前可用结合疫苗中未包含的肺炎链球菌血清型。下一代肺炎球菌结合疫苗有潜力扩展对疾病致病血清型的疫苗覆盖。

This expansion builds on the companies' existing collaboration to develop and commercialize a PCV21 pediatric vaccine, for which the phase 3 clinical program commenced last week. This vaccine candidate is the first-ever PCV containing more than 20 serotypes to enter a phase 3 clinical study in infants and toddlers.

这次扩展建立在公司现有的合作基础上,以开发和商业化一种PCV21儿童疫苗,该疫苗的3期临床项目上周开始。该疫苗候选者是首个进入婴儿和幼儿3期临床研究的含有超过20种血清型的PCV。

Thomas Triomphe
Executive Vice President, Vaccines, Sanofi
"Given the vast unmet public health needs in IPD, we're delighted to expand this collaboration and continue our pursuit of innovative work in PCV. Our collaboration leverages SK bioscience's capabilities and Sanofi's expertise in developing and bringing innovative vaccines to people worldwide with the collective aim of reducing the global impact of pneumococcal disease."

托马斯·特里昂菲
赛诺菲安万特疫苗事业部执行副总裁
“鉴于在侵袭性肺炎链球菌病(IPD)方面存在巨大的未满足公共卫生需求,我们很高兴能够扩大这项合作,并继续追求在PCV方面的创新工作。我们的合作利用了SK生物科学的能力和赛诺菲在开发和向全球民众提供创新疫苗方面的专业知识,共同旨在减少肺炎链球菌疾病对全球的影响。”

Jaeyong Ahn
CEO and President of SK bioscience
"We're thrilled about the expansion of our collaboration with Sanofi, which serves as the core of our strategy to develop new solutions to combat pneumococcal disease. The ongoing expansion of our state-of-the-art manufacturing base, cofinanced by Sanofi, will support launch of PCV21 and future next generation vaccines."

安在永
SK生物科学首席执行官兼总裁
“我们对与赛诺菲安万特合作的扩展感到非常兴奋,这也是我们策略的核心,旨在开发新解决方案以应对肺炎球菌疾病。我们与赛诺菲共同融资的先进制造基地的不断扩展,将支持PCV21的推出以及未来下一代生物-疫苗的问世。”

The PCV21 phase 3 program is based on positive phase 2 results communicated last year and will include more than 7,700 infants, toddlers, young children and adolescents across multiple geographies, including the US, Europe, Australia, Asia, and Latin America.

PCV21第3阶段计划基于去年公布的正面第2阶段结果,将在多个地区招募超过7,700名婴儿、幼儿、儿童和青少年,包括美国、欧洲、澳洲、亚洲和拉丁美洲。

Under the terms of their expanded agreement, both companies will co-fund research and development costs. Sanofi will pay EUR 50M upfront to SK bioscience, followed by development and commercial milestone payments. Once registered, Sanofi will commercialize the vaccines worldwide except for South Korea, where SK bioscience will have commercial exclusivity. SK bioscience will receive royalty payments on product sales outside South Korea.

根据双方扩展协议的条款,两家公司将共同承担研发成本。赛诺菲将向Sk bioscience预付5000万EUR,随后是开发和商业里程碑付款。一旦注册,赛诺菲将在全球范围内销售这些生物-疫苗,唯独在韩国,Sk bioscience将拥有商业独占权。Sk bioscience将在韩国以外的产品销售中获得版税支付。

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

关于赛诺菲安万特
我们是一家创新的全球医疗保健公司,驱动我们的是一个目标:我们追求科学的奇迹,以改善人们的生活。我们全球的团队致力于通过将不可能变为可能来改变医疗实践。我们为全球数百万人提供潜在改变生活的治疗选项和拯救生命的疫苗保护,同时将可持续发展和社会责任置于我们雄心的核心。
赛诺菲在欧元区证券交易所上市,代码为:SAN,并在纳斯达克上市,代码为:SNY

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Léo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com

媒体关系
桑德琳·格恩杜尔 | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@赛诺菲安万特.com
莱奥·勒布尔希斯 | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | + 1 516 521 2929 | timothy.gilbert@赛诺菲安万特.com

Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com

投资者关系
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@赛诺菲安万特.com
阿利泽·凯瑟里安 | + 33 6 47 04 12 11 | alize.kaisserian@赛诺菲安万特.com
费利克斯·劳舍 | + 1 908 612 7239 | felix.lauscher@赛诺菲安万特.com
Keita Browne | + 1 781 249 1766 | keita.browne@赛诺菲安万特.com
娜塔莉·范 | + 33 7 85 93 30 17 | nathalie.pham@赛诺菲安万特.com
塔里克·埃尔戈特尼 | + 1 617 710 3587 | tarik.elgoutni@赛诺菲安万特.com

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

赛诺菲安万特前瞻性声明
本新闻稿包含1995年私人证券诉讼改革法案的修订版中定义的前瞻性声明。前瞻性声明是指非历史事实的陈述。这些声明包括预测和估计及其基本假设,关于未来财务结果、事件、运营、服务、产品开发及潜力的计划、目标、意图和预期的声明,以及关于未来表现的声明。前瞻性声明通常以"期待"、"预期"、"相信"、"打算"、"估计"、"计划"以及类似表达的词语加以识别。尽管赛诺菲的管理层相信这些前瞻性声明中反映的期望是合理的,但投资者应谨慎对待前瞻性信息和声明,因为它们受各种风险和不确定性的影响,其中许多是难以预测的,且通常超出赛诺菲的控制,这可能导致实际结果和发展与前瞻性信息和声明中表达的内容、暗示的内容或预测的内容大相径庭。这些风险和不确定性包括但不限于,研究和开发固有的不确定性、未来临床数据和分析,包括上市后,监管机构(如FDA或EMA)的决定,关于是否以及何时批准任何药物、设备或生物应用的任何此类产品候选者的相关申请,以及他们对标签和其他可能影响此类产品候选者的可用性或商业潜力的事务的决定,产品候选者如果获得批准可能不会成功商业化,治疗替代品的未来批准和商业成功,赛诺菲从外部增长机会中获益的能力,完成相关交易和/或获得监管批准的能力,知识产权及任何相关待决或未来诉讼的风险,以及此类诉讼的最终结果,汇率和当前利率的变化趋势,经济和市场条件的波动,成本控制计划及其后续变更,以及疫情或其他全球危机可能对我们、我们的客户、供应商、承包商和其他合作伙伴、以及任何一个的财务状况及我们的员工和全球经济的整体影响。这些风险和不确定性还包括赛诺菲向SEC和AMF提交的公开文件中讨论或识别的不确定性,包括在赛诺菲截至2023年12月31日的年度报告的“风险因素”和“关于前瞻性声明的警示说明”中列出的内容。除非根据适用法律要求,否则赛诺菲不承担更新或修订任何前瞻性信息或声明的义务。

All trademarks mentioned in this press release are the property of the Sanofi group.

本新闻稿中提到的所有商标均为赛诺菲集团的财产。

Attachment

附件

  • Press Release
  • 新闻稿

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发